23 Feb Cellino
Nabiha Saklayen, CEO
Oct. 8 | 11:45am | FLW Ballroom G
Cambridge, MA
(Private)
Cellino is building an autonomous biomanufacturing platform for personalized regenerative medicines derived from autologous induced pluripotent stem cells (iPSCs), which can be differentiated into a wide range of cell and tissue types to treat conditions including Parkinson’s disease, spinal cord injury, and age-related macular degeneration. Current approaches to manufacturing iPSC-derived therapies are manual and artisanal and are not scalable to meet the needs of growing patient populations. Cellino’s AI-guided platform makes in-process decisions using image-guided machine learning (ML) algorithms and removes unwanted cells using laser-induced bubbles. This avoids contamination by enabling passage-free cell culture, offers single-cell precision, is closed-compatible using proprietary, patient-specific cell cassettes, and requires minimal operator oversight. This process brings a significant cost reduction in iPSC manufacturing compared to manual methods. Cellino’s platform automates iPSC manufacturing to make “Your cells, your cure” a reality for patients.
